SS Innovations International (NASDAQ: SSII) is gaining commercial traction with its SSi Mantra surgical robotic platform, according to recent comments from CEO Dr. Sudhir Srivastava in an interview with The Motley Fool. The company has now performed more than 15,000 procedures using its systems, including approximately 750 cardiac surgeries, signaling growing adoption in both general and specialized surgical fields. The disclosure matters because it demonstrates that SS Innovations is moving beyond early-stage development and into broader clinical use, a key milestone for any medical device company seeking to challenge established competitors.
A particularly noteworthy element of the strategy is the company’s push into telesurgery. More than 200 telesurgeries have been performed on the SSi Mantra platform, including 27 cardiac procedures. This capability could extend specialist surgical expertise to underserved communities, where access to highly trained surgeons is often limited. By enabling remote operations, SS Innovations is positioning itself at the intersection of robotics and telemedicine, two areas with significant potential to reshape healthcare delivery. Srivastava also highlighted the platform’s differentiated engineering, including 4K 3D visualization, surgeon-controlled anatomical imaging, and a modular design that supports up to five robotic arms. These features are designed to give surgeons greater flexibility and control during complex procedures.
Financially, the company is experiencing strong momentum. First-half 2026 revenue increased approximately 66% year-over-year to about $25 million, a figure that underscores rising demand for the SSi Mantra system. To support further growth, SS Innovations is preparing to expand its Indian manufacturing capacity through a planned 10-acre facility, with the goal of bringing additional production capabilities in-house. This vertical integration could help the company control costs and scale more efficiently as order volumes rise.
Regulatory progress is another critical piece of the growth story. The company is advancing applications in Europe and the United States, with management targeting international expansion through direct sales and opportunities in ambulatory surgery centers. Success in these markets would significantly broaden the addressable market for SS Innovations and provide a pathway to compete with larger, entrenched players in the surgical robotics space. For investors and industry observers, the combination of clinical adoption, technological differentiation, and geographic expansion makes SS Innovations a company to watch. As the SSi Mantra platform continues to accumulate real-world evidence and regulatory clearances, its ability to capture share in the global robotic surgery market will depend on execution across manufacturing, sales, and clinical validation. The latest figures suggest the company is making tangible progress on multiple fronts.
